PDCD1 and hepatocellular carcinoma: Anti-programmed death ligand-1 (PD-L1) atezolizumab plus anti-vascular endothelial growth factor (VEGF) bevacizumab and anti-programmed cell death protein 1 (PD-1) camrelizumab plus anti-VEGF receptor 2 (VEGFR2) rivoceranib demonstrated prolonged overall survival and progression-free survival compared with sorafenib that had been the only therapeutic option for unresectable HCC since 2008 [8,9,10].